Get notified when SKYE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Formal Nasdaq notice of non-compliance with minimum bid price requirement triggers delisting risk if not cured within 180 days.
Skye Bioscience receives Nasdaq delisting warning over sub-$1 stock price
Filed March 19, 2026 · Period ending March 17, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Skye on March 17 that its stock bid price stayed below $1.00 for 30 consecutive days, violating minimum listing requirements. The stock continues trading under SKYE while the company addresses the deficiency.
Item 3.01 verify on EDGAR → -
high
Company has until September 14, 2026 (180 days) to regain compliance by maintaining a bid price of $1.00+ for 10 consecutive business days. A reverse stock split must be completed at least 10 business days before the deadline.
Item 3.01 verify on EDGAR → -
medium
If Skye fails to comply by September, it may qualify for a second 180-day extension by meeting all other Nasdaq Capital Market standards and notifying Nasdaq of its cure plan.
Item 3.01 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade SKYE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify